AstraZeneca admits flaws in its vaccine, will it pay on the stock market?
The pharmaceutical company AstraZeneca and the University of Oxford have revealed errors in the manufacture and administration of the doses of their vaccine against Covid-19 and, therefore, doubts surrounding their effectiveness. Interestingly, the volunteers who received the faulty dose showed higher rates of efficacy of the vaccine, which has raised suspicions in the financial markets.
At the moment, the AstraZeneca share price has barely felt an impact from this news on the London Stock Exchange, although it did register a 0.8% drop to GBP 7.68. Larger losses were suffered by the pharmaceutical company in the pre opening of the New York Stock Exchange where the American Depositary Receipts (ADR) of AstraZeneca fell 1.67% to 52.60 dollars.
This stumbling block on the part of the company in its search for the most anticipated vaccine in the world could complicate the future authorization to commercialize it. This could be especially true, considering in the United States, Pfizer and Moderna will foreseeably be favored since their vaccines have, so far, shown greater efficacy without any currently known error in the tests. Therefore, the future of AstraZeneca on the stock market does not look very favorable at this time.
Source: Admiral Markets MetaTrader 5. Astrazeneca ADR CFD Daily Chart. Data range: from May 10, 2016, to November 27, 2020. Prepared on November 27, 2020, at 11:40 am CET. Keep in mind that past returns do not guarantee future returns.
Do you think AstraZeneca will drop to the $50 support? With Admiral Markets UK Ltd, you can speculate on AstraZeneca share price movements both up and down using Contracts for Difference (CFDs). If you want to start you have two options: open a free demo account with virtual money or open a real trading account by clicking on the following banner:
INFORMATION ON ANALYTICAL MATERIALS:
The data provided provides additional information on all analyzes, estimates, forecasts, forecasts, market reviews, weekly outlooks or other evaluations or similar information (hereinafter "Analysis") published on the Admiral Markets website. Before making any investment decisions, pay close attention to the following:
1. This is a marketing communication. The content is posted for informational purposes only and should not be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on pre-dissemination of investment research.
2. Each investment decision is made by each client alone, while Admiral Markets UK Ltd (Admiral Markets) will not be liable for any loss or damage arising from such a decision, whether based on content or not.
3. In order to protect the interests of our clients and the objectivity of the Analysis, Admiral Markets has established relevant internal procedures for the prevention and management of conflicts of interest.
4. The analysis is prepared by an independent analyst, Carolina Caro, SEO implementer (hereinafter "Author") based on personal estimates.
5. While all reasonable efforts are made to ensure that all sources of content are reliable and that all information is presented, as much as possible, in an understandable, timely, accurate, and complete manner, Admiral Markets does not guarantee accuracy. or integrity of any information contained in the Analysis.
6. Any past performance or modelling of the financial instruments indicated in the content should not be construed as an express or implied promise, guarantee, or implication of Admiral Markets for any future performance. The value of the financial instrument may rise and fall, and the preservation of the asset's value is not guaranteed.
7. Leveraged products (including contracts for difference) are speculative in nature and may generate profit or loss. Before you start trading, make sure you fully understand the risks.
